These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10537061)

  • 21. Therapeutic effects of cystamine in a murine model of Huntington's disease.
    Dedeoglu A; Kubilus JK; Jeitner TM; Matson SA; Bogdanov M; Kowall NW; Matson WR; Cooper AJ; Ratan RR; Beal MF; Hersch SM; Ferrante RJ
    J Neurosci; 2002 Oct; 22(20):8942-50. PubMed ID: 12388601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications.
    Karpuj MV; Becher MW; Steinman L
    Neurochem Int; 2002 Jan; 40(1):31-6. PubMed ID: 11738470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia.
    Browne SE; Bowling AC; MacGarvey U; Baik MJ; Berger SC; Muqit MM; Bird ED; Beal MF
    Ann Neurol; 1997 May; 41(5):646-53. PubMed ID: 9153527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Huntington's chorea: selective depletion of activity of angiotensin coverting enzyme in the corpus striatum.
    Arregui A; Bennett JP; Bird ED; Yamamura HI; Iversen LL; Snyder SH
    Ann Neurol; 1977 Oct; 2(4):294-8. PubMed ID: 214022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements.
    DiProspero NA; Chen EY; Charles V; Plomann M; Kordower JH; Tagle DA
    J Neurocytol; 2004 Sep; 33(5):517-33. PubMed ID: 15906159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine.
    Kahlem P; Green H; Djian P
    Mol Cell; 1998 Mar; 1(4):595-601. PubMed ID: 9660943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain.
    Dowie MJ; Grimsey NL; Hoffman T; Faull RL; Glass M
    J Chem Neuroanat; 2014 Sep; 59-60():62-71. PubMed ID: 24978314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.
    Kumar A; Kneynsberg A; Tucholski J; Perry G; van Groen T; Detloff PJ; Lesort M
    Exp Neurol; 2012 Sep; 237(1):78-89. PubMed ID: 22698685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
    Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
    Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease.
    Jeitner TM; Bogdanov MB; Matson WR; Daikhin Y; Yudkoff M; Folk JE; Steinman L; Browne SE; Beal MF; Blass JP; Cooper AJ
    J Neurochem; 2001 Dec; 79(5):1109-12. PubMed ID: 11739625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.
    McConoughey SJ; Basso M; Niatsetskaya ZV; Sleiman SF; Smirnova NA; Langley BC; Mahishi L; Cooper AJ; Antonyak MA; Cerione RA; Li B; Starkov A; Chaturvedi RK; Beal MF; Coppola G; Geschwind DH; Ryu H; Xia L; Iismaa SE; Pallos J; Pasternack R; Hils M; Fan J; Raymond LA; Marsh JL; Thompson LM; Ratan RR
    EMBO Mol Med; 2010 Sep; 2(9):349-70. PubMed ID: 20665636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel role of transglutaminase 1 in corpora amylacea formation?
    Wilhelmus MM; Verhaar R; Bol JG; van Dam AM; Hoozemans JJ; Rozemuller AJ; Drukarch B
    Neurobiol Aging; 2011 May; 32(5):845-56. PubMed ID: 19464759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The loss of beta II-protein kinase C in the striatum from patients with Huntington's disease.
    Hashimoto T; Kitamura N; Saito N; Komure O; Nishino N; Tanaka C
    Brain Res; 1992 Jul; 585(1-2):303-6. PubMed ID: 1387337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain.
    Maat-Schieman ML; Dorsman JC; Smoor MA; Siesling S; Van Duinen SG; Verschuuren JJ; den Dunnen JT; Van Ommen GJ; Roos RA
    J Neuropathol Exp Neurol; 1999 Feb; 58(2):129-37. PubMed ID: 10029096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An immunohistochemical study of tissue transglutaminase in gliomas with reference to their cell dying processes.
    Iwaki T; Miyazono M; Hitosumatsu T; Tateishi J
    Am J Pathol; 1994 Oct; 145(4):776-81. PubMed ID: 7524329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct nuclear localization and activity of tissue transglutaminase.
    Lesort M; Attanavanich K; Zhang J; Johnson GV
    J Biol Chem; 1998 May; 273(20):11991-4. PubMed ID: 9575137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases?
    Cooper AJ; Jeitner TM; Gentile V; Blass JP
    Neurochem Int; 2002 Jan; 40(1):53-67. PubMed ID: 11738472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autopsy case of concurrent Huntington's disease and neurofibromatosis type 1.
    Kawakami I; Katsuse O; Aoki N; Togo T; Suzuki K; Isojima D; Kondo D; Iseki E; Kosaka K; Akiyama H; Hirayasu Y
    Psychogeriatrics; 2014 Mar; 14(1):81-6. PubMed ID: 24528652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
    Prime ME; Andersen OA; Barker JJ; Brooks MA; Cheng RK; Toogood-Johnson I; Courtney SM; Brookfield FA; Yarnold CJ; Marston RW; Johnson PD; Johnsen SF; Palfrey JJ; Vaidya D; Erfan S; Ichihara O; Felicetti B; Palan S; Pedret-Dunn A; Schaertl S; Sternberger I; Ebneth A; Scheel A; Winkler D; Toledo-Sherman L; Beconi M; Macdonald D; Muñoz-Sanjuan I; Dominguez C; Wityak J
    J Med Chem; 2012 Feb; 55(3):1021-46. PubMed ID: 22224594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain.
    Kim SY; Marekov L; Bubber P; Browne SE; Stavrovskaya I; Lee J; Steinert PM; Blass JP; Beal MF; Gibson GE; Cooper AJ
    Neurochem Res; 2005 Oct; 30(10):1245-55. PubMed ID: 16341586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.